--- a
+++ b/clusters/3009knumclusters/clust_44.txt
@@ -0,0 +1,362 @@
+Pregnant females are ineligible
+Female patients who are pregnant are ineligible
+Pregnant female patients are not eligible for this study
+Female patients who are pregnant are excluded; patients should not be pregnant or plan to become pregnant while on treatment; a pregnancy test prior to enrollment is required for female patients of childbearing potential
+Female patients who are pregnant are ineligible
+Pregnant women are excluded from this study
+Pregnant women are excluded from this study
+Pregnant
+Pregnant women are excluded from this study
+Pregnant women are excluded
+Pregnant women
+Pregnant women
+Male pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant. The patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant.
+TREATMENT: Pregnant
+Pregnant women
+Pregnant women are excluded from this research; the male partner should use a condom
+Patients who are breastfeeding, pregnant, or planning to become pregnant from the time of informed consent until 6 months after the final study dose is administered
+Pregnant patients
+Pregnant women are excluded from this study
+Patients who are pregnant or lactating or who are planning to become pregnant during the course of the study are excluded.
+Pregnant women are excluded from this study
+Any patient who is pregnant or who may have plans to become pregnant
+Pregnant or planning to become pregnant during period of study participation
+Pregnant women are excluded from this study
+Not pregnant
+Women must not be pregnant or breast feeding; pregnant women are excluded from this study
+Women known to be pregnant
+Women who are pregnant are ineligible.
+Pregnant women
+Pregnant women
+Pregnant women are excluded from this study
+Patients who are pregnant
+Patients who are pregnant
+Pregnant women
+Women who are pregnant.
+Patients who are pregnant.
+Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
+Pregnant
+Subject is pregnant or trying to become pregnant.
+Non-pregnant.
+Pregnant women are excluded from this study
+Pregnant or breast feeding women; women desiring to become pregnant within the time frame of the study are also excluded
+Pregnant women are excluded from this study
+Pregnant women are excluded from this study as the proposed treatment has not been well studied in pregnant subjects.
+Pregnant women are excluded from this study
+Pregnant women are excluded from this study
+If you are pregnant, you will not be enrolled on this study
+Pregnant women are excluded from this study
+Currently pregnant
+Pregnancy status will be obtained at time of consent as is routine for all radiation patients; pregnant women are excluded from this study
+Patient is known to be pregnant
+Patient is pregnant
+Pregnant women are excluded from this study
+Women who are pregnant
+Pregnant women
+Pregnant women are excluded
+Pregnant women
+A pregnant or lactating female or possibly pregnant women, or men or women wishing to have children during the study period;
+Pregnant women
+Patient is pregnant
+Pregnant females are excluded
+Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
+Pregnant patients will be excluded from this study
+Pregnant women are excluded from this study
+Pregnant women are excluded from this study
+CERITINIB EXCLUSION CRITERIA: Pregnant or nursing women, or women intending to become pregnant during the study (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test); pregnant women are excluded from this study; nursing women are excluded unless they discontinue breastfeeding during the study
+REGORAFENIB EXCLUSION CRITERIA: Pregnant or nursing women, or women intending to become pregnant during the study (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test); pregnant women are excluded from this study; nursing women are excluded unless they discontinue breastfeeding during the study
+Women should not become pregnant or breastfeed while on this study
+Pregnant women
+Pregnant women are excluded from this study
+Patients who are pregnant
+Pregnant women are excluded from this study
+Subjects must not be pregnant
+Subjects who are pregnant or may become pregnant
+Pregnant women are excluded from this study
+Pregnant women are excluded
+Are pregnant
+Patient is not pregnant
+Pregnant women, women planning to become pregnant and women that are nursing
+Pregnant women, women planning to become pregnant and women that are nursing
+Pregnant women are excluded from this study
+Female subjects who are pregnant or planning to become pregnant during the course of SABR
+Patients who are pregnant
+Females who are pregnant
+Pregnant women are excluded from enrollment on this study
+Pregnant women
+Women who are planning to become pregnant or breast feed during the trial
+Pregnant women are not eligible to participate in this study
+Women who are pregnant will be excluded (Turnstile II)
+Women who are pregnant
+Pregnant women, women planning to become pregnant and women that are nursing
+Pregnant women are excluded from this study
+Women who are pregnant will be excluded (Turnstile II)
+Patients who are pregnant
+Pregnant women
+Females who are pregnant
+Pregnant women are excluded from this study
+Pregnant women, women planning to become pregnant and women that are nursing
+Pregnant women, women planning to become pregnant and women that are nursing
+Pregnant
+Pregnant women, women planning to become pregnant and women that are nursing
+Patients who are pregnant
+Patient who is pregnant
+Pregnant patients (Cohort D)
+Pregnant women are excluded from this study
+Pregnant women must not take part in this trial and will be considered as screening failures.
+Not pregnant
+Pregnant women
+DONOR: Pregnant women
+Pregnant at time of or within prior year of diagnosis
+ENROLLMENT: Pregnant females.
+Pregnant women
+Not pregnant
+Pregnant women
+Female patients who are pregnant are ineligible
+Female patients who are pregnant are ineligible
+Female patients who are pregnant are ineligible
+Pregnancy: pregnant women are excluded from this study; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately; women who are pregnant or breastfeeding are excluded
+Pregnant women
+Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
+Pregnant women are excluded from this study
+Pregnant women are excluded from this study
+Pregnant women are excluded from this study
+Patients known or found to be pregnant
+Female patients who are pregnant are not eligible for this study
+Pregnant women
+Pregnant patients are ineligible
+Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.
+Pregnant or nursing women. NOTE: If a woman became pregnant or suspects she is pregnant while participating in this study, she must inform her treating physician immediately.
+Not pregnant. Must agree not to become pregnant until at least 6 months after ceasing study treatment
+Pregnancy, or planning to become pregnant
+Pregnant women
+not be pregnant
+Pregnant women are excluded from this study
+Pregnant female
+Pregnant women are excluded from study
+Pregnant women are excluded from this study
+Female patients who are pregnant are ineligible
+Patients who are pregnant
+Pregnant
+Pregnant or breastfeeding women; women desiring to become pregnant within the timeframe of the study are also excluded.
+Pregnant women are excluded from this study
+Pregnant patients
+Pregnant women are excluded from this study
+Pregnant women
+Pregnant women
+Are not pregnant and do not plan to become pregnant during the clinical trial
+Subjects must not be pregnant
+Patient is pregnant
+Pregnant women are excluded from this study
+Patient is pregnant or lactating; pregnant women are excluded from this study
+Patient is a pregnant woman
+Pregnant women are excluded from this study
+Are pregnant
+Female patients who are pregnant are not eligible
+Pregnant women, women planning to become pregnant and women that are nursing
+Pregnant females are excluded
+Females who are pregnant
+Women who are pregnant
+Pregnant women are excluded from this study
+Women of child-bearing potential who are pregnant or breastfeeding; additionally, patients that become pregnant while on study protocol will be discontinued immediately
+Patient is a pregnant woman (pregnant women are excluded from this study)
+Pregnant women are excluded from this study
+Pregnant women
+Patients who are pregnant
+Patients who are pregnant;
+The donor is pregnant or lactating, or was pregnant in the previous 6 months, or intends to get pregnant during the study or within 30 days after the last dose of study drug
+Pregnant women.
+Females who are pregnant
+Pregnant women
+Pregnant women are excluded from this study
+Pregnant women
+Pregnant
+Pregnant
+Pregnant women
+Pregnant women
+Pregnant or lactating women, or women intending to become pregnant during the study
+Pregnant women are excluded from this study
+Pregnant women
+Pregnant women
+Female patients who are pregnant are ineligible
+Subjects who are pregnant.
+Females: neither pregnant nor intending to become pregnant during the course of the study, defined as:
+Pregnant or planning to become pregnant
+Pregnancy or planning to become pregnant
+Pregnant women are excluded from this study
+Women must not be able to become pregnant for the duration of the study.
+Pregnant women
+Pregnant women are excluded from this study
+Pregnant females
+Women who are pregnant
+Patients who are pregnant
+Patients who are pregnant may not be treated on this study
+Pregnant women
+Nursing or pregnant females; should a woman become pregnant or suspect she is pregnant while participating in the study, she should inform her treating physician immediately
+Not pregnant
+Women who are pregnant
+Pregnant women
+Pregnant women are eligible to participate in this study
+Pregnant women
+Pregnant women
+Females who are pregnant
+Pregnant participants will not be entered on this study
+Subject is pregnant at time of enrollment
+Pregnant women
+Pregnant women will be excluded
+Those who are currently pregnant, have been pregnant within the last 6 months, or are planning to become pregnant in the next 6 months.
+YBCS: Women who are pregnant at recruitment will be excluded from this study; however, during the course of follow up, women who become pregnant will be included
+Not currently pregnant or planning to become pregnant throughout the duration of cancer treatment
+Patient is pregnant
+Pregnant women are excluded from this study
+Pregnant patients will be excluded
+Pregnant women
+Non-pregnant females
+Pregnant women
+Pregnant
+Pregnant patients
+A positive pregnancy test, currently pregnant or planning to become pregnant in the next three months
+Pregnant women
+Patients who are pregnant
+Pregnant women
+Are pregnant
+Pregnant
+Pregnant
+Pregnant
+Women who self-report to be pregnant\r\n* As this is an observational study, we will not be performing a pregnancy test, participants will be asked if they are or are not pregnant
+Women who are pregnant
+Pregnant women
+Pregnant
+Currently pregnant
+Pregnant or thinking about becoming pregnant during the study period
+Currently pregnant or planning to become pregnant
+Pregnant
+Pregnant women
+Patients who are pregnant
+Women who are pregnant or breastfeeding or planning to become pregnant or breastfeed during the period of treatment and for 112 days following the last dose of sotatercept
+Currently pregnant
+pregnant
+Self-report that they are not pregnant or planning to become pregnant in the next four months
+Pregnant females are ineligible; all subjects of childbearing potential will be asked if they are pregnant or could be pregnant; the patient must respond “no” to continue with radiation and to participate in this clinical study
+Pregnant
+Pregnant or planning to become pregnant during the course of the study
+Pregnant
+Patients who are pregnant
+Pregnant women
+Participants who are pregnant
+Pregnant patients-excluded by history
+Are pregnant or intend to become pregnant during the study period
+Pregnant patients
+Non-pregnant
+Plan to become pregnant in the next two years, as mammography is not typically performed for screening pregnant women
+Patients who are currently pregnant
+PRELIMINARY TEST: Not currently pregnant or was not pregnant in the last 3 months
+Not currently pregnant or was not pregnant in the last 3 months
+Pregnant women
+Pregnant or possibly pregnant
+Currently pregnant
+They do not plan to become pregnant during the study; and
+Pregnant female
+FOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Pregnant female
+Pregnant female
+Being pregnant
+Not pregnant or planning on becoming pregnant
+Pregnant women
+Pregnant women are naturally excluded given condition of cisplatin therapy
+Women who are pregnant
+Pregnant or planning to become pregnant within the next year
+Pregnant women
+Currently pregnant. However, participants enrolled who become pregnant after randomization can remain on the study.
+If female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study
+Being pregnant or planning on becoming pregnant within the next year
+Pregnant
+Pregnant women
+Are pregnant
+Pregnant women
+Pregnant women
+Currently pregnant
+Pregnant women are excluded from this study
+Women who are pregnant or plan to become pregnant in the study period
+A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose.
+Pregnant patients
+Women on study must be neither pregnant nor nursing nor expected to become pregnant during therapy; for premenopausal women, negative pregnancy test within 14 days of RT is required
+Pregnant women
+Participants who are pregnant
+Pregnant women
+Pregnant
+Participants who are pregnant
+Pregnant women are excluded
+Patient is pregnant
+Pregnant patients will be included
+Are pregnant
+Women who are pregnant
+Not pregnant
+Pregnant patients
+Patient is not pregnant
+Pregnant patients
+Pregnant or lactating women: pregnant women are excluded from this study because the effects of [18F] FAZA in pregnancy are not known. A urine or serum pregnancy test will be performed before accrual after informed consent is obtained.
+Men and non-pregnant women.
+Pregnant women are excluded from participating in this study
+Pregnant women or breastfeeding\r\n* Potential subjects will be asked if they are pregnant; verbal confirmation of pregnancy will be sufficient
+The subject is pregnant
+Subjects who have contraindications for receiving Y-90 therapy and any routine procedures and imaging associated with Y-90 therapy, including subjects who are pregnant or are planning to become pregnant, will not be eligible to participate in this study. Female subjects who are of childbearing potential should inform her treating physician should she become pregnant at any time during the course of the study
+Pregnancy; (pregnant women will be excluded from this study)
+Pregnant women are excluded from this study
+Pregnant women are excluded
+Pregnant women are excluded from this study
+Patients who are pregnant or are trying to become pregnant are excluded from this study
+Pregnant
+Currently pregnant
+Participants who are pregnant
+Women who are currently pregnant
+Pregnant women
+Patients who are pregnant
+Women who are pregnant
+Women who are pregnant or planning to become pregnant during the trial
+Pregnant women
+Pregnant
+Pregnant women are excluded
+Is pregnant;
+Patients must not be pregnant
+Pregnant women
+Pregnant women
+Patients who are pregnant
+Pregnant
+Pregnant
+Women who are pregnant
+Women who are pregnant or trying to get pregnant
+Patients who are pregnant
+Pregnant patients
+Pregnant women are excluded from this study
+Females must not be pregnant
+Pregnant patients
+Not pregnant
+Patients who are pregnant are excluded
+Pregnant patients are to be excluded
+Pregnant women are excluded from participation due to inability to participate in required chemotherapy regimen
+Patients who are pregnant
+Pregnant women
+Patients who are known to be pregnant.
+Women who are pregnant will be excluded from the trial
+Are pregnant
+Pregnant patients
+Pregnant
+Pregnant
+Patients who are pregnant
+Women who are pregnant
+Be pregnant
+Patient who is pregnant
+Pregnant women.
+Women who are pregnant, intend to become pregnant within 3 months of the study period, or who are breastfeeding
+Are pregnant
+Patients pregnant at the time of enrollment
+Participants who are currently pregnant
+Women who are pregnant, intend to become pregnant within 3 months of the study period, or who are breastfeeding
+Pregnant patients are excluded
+Pregnant women
+Not pregnant
+PHASE I: Pregnant women will be eligible to participate
+Women who are pregnant or intending to become pregnant during the study
+Currently pregnant
+Pregnant women
+Women who are pregnant or lactating, if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus